Withaphysalin A
Based on 1 Customer Validation
Withaphysalin A is a withanolide compound with anti-inflammatory and antioxidant activities. Withaphysalin A inhibits LPS (HY-D1056)-induced nuclear translocation of NF-κB p65, as well as phosphorylation of STAT3, ERK, JNK and p38 MAPK. Withaphysalin A upregulates the expression of HO-1. Withaphysalin A inhibits LPS-induced production of NO, PGE2, IL-1β, IL-6 and TNF-α. Withaphysalin A downregulates LPS-induced expression of iNOS and COX-2. Withaphysalin A interacts with B-cell activating factor protein (BAFF) to exert inhibitory effects. Withaphysalin A exhibits ELOVL6 inhibitory activity. Withaphysalin A can be used in the research of inflammatory diseases, nephrotic syndrome and chronic myeloid leukemia.
For research use only. We do not sell to patients.
- Purity: 98%
- CAS No.: 57423-72-0
- Formula: C28H34O6
- Molecular Weight:466.57
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Withaphysalin A (0-50 μM; 1 h) potently inhibits LPS-induced NO production in RAW264.7 cells, with an IC50 of 20.12 μM, and suppresses LPS-induced PGE2 production[1].
Withaphysalin A (0-50 μM; 1 h) dose-dependently inhibits LPS-induced production of IL-6, TNF-α, and IL-1β in RAW264.7 cells, with both protein and mRNA levels suppressed[1].
Withaphysalin A (0-50 μM; 1) dose-dependently inhibits LPS-induced expression of iNOS and COX-2 (at both protein and mRNA levels) in RAW264.7 cells[1].
Withaphysalin A (0-50 μM; 1 h) inhibits LPS-induced phosphorylation of ERK, JNK, p38 MAPK, and STAT3, and induces HO-1 protein expression in LPS-stimulated RAW264.7 cells[1].
Withaphysalin A (50 μM; 1 h) inhibits LPS-induced nuclear translocation of NF-κB p65 in RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LPS-stimulated mouse macrophage RAW264.7 cells
-
Concentration:0, 12.5, 25, 50 μM
-
Incubation Time:1 h
-
Result:Significantly reduced LPS-induced PGE2 release at all tested concentrations compared to the LPS-only group.
Dose-dependently suppressed LPS-induced release of IL-6, TNF-α, and IL-1β protein levels.
-
Cell Line:LPS-stimulated mouse macrophage RAW264.7 cells
-
Concentration:0, 12.5, 25, 50 μM
-
Incubation Time:1 h
-
Result:Dose-dependently reduced LPS-induced mRNA expression of IL-6, TNF-α, and IL-1β.
-
Cell Line:LPS-stimulated mouse macrophage RAW264.7 cells
-
Concentration:0, 12.5, 25, 50 μM
-
Incubation Time:1 h
-
Result:Dose-dependently reduced LPS-induced iNOS and COX-2 protein expression, with significant suppression.
Significantly inhibited p-JNK、p-p38、p-ERK、MAPK、STAT3 phosphorylation.
Dose-dependently increased LPS-induced HO-1 protein expression.
-
Cell Line:LPS-stimulated mouse macrophage RAW264.7 cells
-
Concentration:50 μM
-
Incubation Time:1 h
-
Result:Significantly reduced LPS-induced nuclear translocation of NF-κB p65 at 50 μM.
Chemical Information
-
CAS No. 57423-72-0
-
Appearance Solid
-
Molecular Weight 466.57
-
Formula C28H34O6
-
Color White to off-white
-
SMILES
CC(CC([C@@]1(OC([C@]23CCC4C([C@@]2(CCC31)O)CC=C5CC=CC([C@]45C)=O)=O)C)O6)=C(C)C6=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li RJ, et al. The Anti-inflammatory Activities of Two Major Withanolides from Physalis minima Via Acting on NF-κB, STAT3, and HO-1 in LPS-Stimulated RAW264.7 Cells. Inflammation. 2017;40(2):401-413. [Content Brief]
[2]. Kardani AK, et al. Inhibition of B-cell activating factor activity using active compounds from Physalis angulata in the mechanism of nephrotic syndrome improvement: A computational approach. Narra J. 2024 Dec;4(3):e859. [Content Brief]
[3]. Tasneem A, et al. Exploring phytochemical inhibitors of fatty acid elongase ELOVL6 for targeted treatment of chronic myeloid leukemia: A comprehensive network-based drug discovery approach. Comput Biol Med. 2026;201:111342. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz